JPWO2020118213A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020118213A5
JPWO2020118213A5 JP2021531818A JP2021531818A JPWO2020118213A5 JP WO2020118213 A5 JPWO2020118213 A5 JP WO2020118213A5 JP 2021531818 A JP2021531818 A JP 2021531818A JP 2021531818 A JP2021531818 A JP 2021531818A JP WO2020118213 A5 JPWO2020118213 A5 JP WO2020118213A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cdk4
resistant
inhibitor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531818A
Other languages
English (en)
Japanese (ja)
Other versions
JP7504097B2 (ja
JP2022511498A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065005 external-priority patent/WO2020118213A1/en
Publication of JP2022511498A publication Critical patent/JP2022511498A/ja
Publication of JPWO2020118213A5 publication Critical patent/JPWO2020118213A5/ja
Application granted granted Critical
Publication of JP7504097B2 publication Critical patent/JP7504097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531818A 2018-12-06 2019-12-06 Cdk4/6阻害剤に耐性の癌を治療するための方法 Active JP7504097B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776323P 2018-12-06 2018-12-06
US62/776,323 2018-12-06
PCT/US2019/065005 WO2020118213A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer resistant to cdk4/6 inhibitors

Publications (3)

Publication Number Publication Date
JP2022511498A JP2022511498A (ja) 2022-01-31
JPWO2020118213A5 true JPWO2020118213A5 (ru) 2022-12-19
JP7504097B2 JP7504097B2 (ja) 2024-06-21

Family

ID=69063871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531818A Active JP7504097B2 (ja) 2018-12-06 2019-12-06 Cdk4/6阻害剤に耐性の癌を治療するための方法

Country Status (15)

Country Link
US (1) US20210330612A1 (ru)
EP (1) EP3890834A1 (ru)
JP (1) JP7504097B2 (ru)
KR (1) KR20210100137A (ru)
CN (1) CN113164779A (ru)
AU (1) AU2019395093A1 (ru)
BR (1) BR112021010110A2 (ru)
CA (1) CA3121930A1 (ru)
EA (1) EA202191283A1 (ru)
IL (1) IL283659A (ru)
JO (1) JOP20210137A1 (ru)
MA (1) MA54388A (ru)
MX (1) MX2021006411A (ru)
SG (1) SG11202105531XA (ru)
WO (1) WO2020118213A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202592A1 (en) * 2020-12-14 2022-06-23 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
AU2016256470B2 (en) * 2015-04-29 2020-10-15 Radius Pharmaceuticals, Inc. Methods of treating cancer
LT3565542T (lt) * 2017-01-05 2024-07-10 Radius Pharmaceuticals, Inc. Polimorfinės rad1901-2hcl formos
CN112423844B (zh) * 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式

Similar Documents

Publication Publication Date Title
JP2018518529A5 (ru)
RU2017140676A (ru) Способы лечения рака
JP2018514549A5 (ru)
Prowell et al. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
CA2554463C (en) Anti-cancer therapies
JP2022071099A5 (ru)
JP2019532011A (ja) Flt3突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
Shah et al. Hormone receptor–positive/human epidermal growth receptor 2–negative metastatic breast cancer in young women: emerging data in the era of molecularly targeted agents
Mondaca et al. FOLFCIS treatment and genomic correlates of response in advanced anal squamous cell cancer
WO2016091165A1 (zh) 治疗非小细胞肺癌的喹啉衍生物
JP7504097B2 (ja) Cdk4/6阻害剤に耐性の癌を治療するための方法
JPWO2020118213A5 (ru)
US20230129787A1 (en) Methods for treating ovarian cancer
Guan et al. Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis
JPWO2020118202A5 (ru)
RU2021116293A (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
Lai et al. Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: a case report
RU2021116084A (ru) Способы лечения рака на моделях, имеющих мутации esr1
Heidenreich et al. Targeted therapy in patients with metastatic male germ cell tumors
US20220226338A1 (en) Methods of Treating Cancer Using CHK1 Inhibitors
CN111789952A (zh) 一种治疗肾透明细胞癌的药物组合物及其应用
Tamborero Noguera et al. Cancer bioMarkers database
WO2019174590A1 (zh) 用于治疗三阴性乳腺癌的喹啉衍生物
우고운 Clinical Implication of Next Generation Sequencing for Patients with Metastatic Breast Cancer
US20240096469A1 (en) Methods of predicting responses to disease treatments